Condition
HFpEF - Heart Failure With Preserved Ejection Fraction
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 29 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
29 shownAlEX-DHF: Ablation and Exercise in Diastolic Heart FailureNCT06650995 · 2027-02-01
RECRUITINGCardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection FractionNCT07693049 · 2026-08-10
RECRUITINGCan Tiny Bubbles Offer an Alternative to Catheters for Assessing Pressures Inside the Heart? Investigating Ultrasound Contrast Agents as Pressure Sensors Against Gold Standard Catheter Pressures in Cardiac Catheterisation Patients.NCT07416279 · 2026-02-01
RECRUITINGUS Benchmarking Clinical StudyNCT07215715 · 2025-09-16
RECRUITINGMOVE-HF MOtivating Physical Activity With BehaVioral Economics in Heart Failure With Preserved Ejection FractionNCT06670001 · 2025-06-05
RECRUITINGCAMEO-FONTAN -Dapagliflozin in the Failing Fontan CirculationNCT06762964 · 2025-05-16
RECRUITINGHeart Failure in Patients With Diabetes: Cells, Crosstalk and ConsequencesNCT06774014 · 2025-02-26
RECRUITINGTailored Exercise Training Study Among Adults With HFpEFNCT07223242 · 2025-02-18
RECRUITINGAI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable MonitorNCT06699056 · 2024-11-21
RECRUITINGHEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection FractionNCT05784753 · 2023-11-20
RECRUITINGCatheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)NCT06125925 · 2023-11-06
RECRUITINGThe Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)NCT07855692 · 2026-10-01
NOT_YET_RECRUITINGExercise-Based Cardiac Rehabilitation for Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)NCT07727096 · 2026-09-01
NOT_YET_RECRUITINGFinerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart FailureNCT07575672 · 2026-07-01
NOT_YET_RECRUITINGDeprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)NCT07298993 · 2026-02-02
ENROLLING_BY_INVITATIONStudy of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary HypertensionNCT07221513 · 2025-12-15
WITHDRAWNTesting the CHAT Program for Patients With Heart FailureNCT06994325 · 2025-07-31
COMPLETEDThe Safety and Efficacy of Pulsed Field Ablation for Patients With Persistent Atrial Fibrillation Comorbid With HFpEF.NCT07077811 · 2025-06-01
ENROLLING_BY_INVITATIONComparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection FractionNCT06914141 · 2025-01-14
COMPLETEDEmulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims DataNCT06914102 · 2025-01-14
COMPLETEDSerum IGF1 on Female HFpEF PatientsNCT07015554 · 2025-01-01
ENROLLING_BY_INVITATIONRole of Colchicine as Anti-Inflammatory Therapy in HFpEFNCT06837623 · 2024-07-01
ACTIVE_NOT_RECRUITINGValidation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary HypertensionNCT06405126 · 2024-02-21
UNKNOWNExercise Magnetic Resonance Imaging in Patients With Obesity Associated Heart FailureNCT06514820 · 2024-01-16
UNKNOWNAtrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac MonitorNCT05745337 · 2023-02-06
UNKNOWNColchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection FractionNCT05637398 · 2022-12-15
COMPLETEDThe Gut Microbiota and Metabolites in HFpEFNCT06645535 · 2022-06-30
ENROLLING_BY_INVITATIONPeripheral Microvascular Blood Flow in ANOCANCT05610410 · 2022-01-01
COMPLETEDIMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)NCT04826159 · 2021-04-21
COMPLETEDCommon interventions
PlaceboDRUG3SemaglutideDRUG215-minutes of sitting during COR ECG AcquistionDEVICE1antiarrhythmic drugDRUG1As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)DRUG1Beta-blockersDRUG1ColchicineDRUG1Colchicine TabletsDRUG1Contrast EchocardiographyOTHER1Conversations Helpful for Awareness of Illness Trajectory (CHAT) InterventionBEHAVIORAL1Dapagliflozin tabletDRUG1Exercise trainingOTHER1Exercise-Based Cardiac RehabilitationBEHAVIORAL1FinerenoneDRUG1Gamification plus competitionBEHAVIORAL1Gamification plus social incentiveBEHAVIORAL1Guideline-Directed Medical TherapyOTHER1HEART CampBEHAVIORAL1HEART Camp ConnectBEHAVIORAL1High-intensity interval trainingBEHAVIORAL1IMB-1018972DRUG1JK07DRUG1Laser speckle contrast analysisOTHER1Medical TherapyDRUG1Moderate-intensity continuous training (MCT)BEHAVIORAL1
Leading sponsors
Brigham and Women's Hospital
2
The First Affiliated Hospital with Nanjing Medical University
2
Weill Medical College of Cornell University
2
Affiliated Hospital of Nantong University
1
Amsterdam UMC, location VUmc
1
Cairo University
1
eMyosound SAS
1
Fundación para la Investigación del Hospital Clínico de Valencia
1
I.M. Sechenov First Moscow State Medical University
1
Imbria Pharmaceuticals, Inc.
1
King's College London
1
KU Leuven
1
Mayo Clinic
1
Nagoya University
1
Peerbridge Health, Inc
1
Trial status mix
RECRUITING11
COMPLETED6
ENROLLING_BY_INVITATION4
NOT_YET_RECRUITING3
UNKNOWN3
ACTIVE_NOT_RECRUITING1
WITHDRAWN1
Phase mix
NA9
PHASE26
PHASE33
PHASE12
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.